Quick Answer
Sarepta Therapeutics, Inc. reported Revenue (ASC 606) of $1.86 billion for fiscal year 2025.
Sarepta Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $1.86B | +4.3% |
| 2024 | $1.79B | +56.2% |
| 2023 | $1.14B | +35.7% |
| 2022 | $843.77M | +37.8% |
| 2021 | $612.40M | +34.3% |
| 2020 | $455.87M | +19.7% |
| 2019 | $380.83M | +26.5% |
| 2018 | $301.03M | +94.7% |
| 2017 | $154.58M | +2751.6% |
| 2016 | $5.42M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $370.04M | -13.9% | -27.9% |
| June 30, 2025 | $513.12M | +42.3% | -16.1% |
| March 31, 2025 | $611.52M | +70.1% | +42.3% |
| September 30, 2024 | $429.77M | +38.9% | +19.2% |
| June 30, 2024 | $360.55M | +50.9% | +0.3% |
| March 31, 2024 | $359.48M | +55.3% | +16.2% |
| September 30, 2023 | $309.32M | +48.9% | +29.4% |
| June 30, 2023 | $238.99M | +13.1% | +3.2% |
- Sarepta Therapeutics, Inc. showed an increase of +4.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2016–2025 period, Sarepta Therapeutics, Inc.’s revenue (asc 606) has grown by 34290.3% (from $5.42 million to $1.86 billion).
- The most recent figure is from Sarepta Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: